Page last updated: 2024-09-05

deferasirox and Candidiasis, Oral

deferasirox has been researched along with Candidiasis, Oral in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Edgerton, M; Kumar, R; Puri, S; Rojas, IG; Salvatori, O	1

Other Studies

1 other study(ies) available for deferasirox and Candidiasis, Oral

Article	Year
Iron Chelator Deferasirox Reduces Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:4 Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Oral; Cell Adhesion; Cells, Cultured; Deferasirox; Drug Repositioning; Epithelial Cells; Female; Gene Expression Regulation, Fungal; Humans; Iron; Iron Chelating Agents; Mice; Mice, Inbred C57BL; Mouth Mucosa; Neutrophils; Oxidative Stress; Saliva; Tongue	2019

Article

Year

Iron Chelator Deferasirox Reduces

Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:4

Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Oral; Cell Adhesion; Cells, Cultured; Deferasirox; Drug Repositioning; Epithelial Cells; Female; Gene Expression Regulation, Fungal; Humans; Iron; Iron Chelating Agents; Mice; Mice, Inbred C57BL; Mouth Mucosa; Neutrophils; Oxidative Stress; Saliva; Tongue

2019